Australian company Hatchtech has announced commercialisation partner, Dr Reddy’s Laboratories, has secured US FDA approval of XEGLYZE (abametapir) for the topical treatment of head lice. …
Latest Video
New Stories
-
TGA approves new indication for GSK's RSV vaccine
April 24, 2025 - - Latest News -
It's important to understand that health technology assessment is not an enabler
April 24, 2025 - - Latest News -
The Dispatched Podcast 'Week/s in Review' - 24 April
April 23, 2025 - - Podcast -
Roche announces historic investment to build US manufacturing base
April 23, 2025 - - Latest News -
US trade agenda looks mostly disinterested in pharmaceuticals
April 23, 2025 - - Latest News -
'Reflecting the experience of people living with cancer, Pfizer’s new campaign Part of the Story seeks to reshape the narrative'
April 23, 2025 - - Latest News -
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 - - Australian Biotech